RJA
ONC

Raymond James & Associates’s BeOne Medicines Ltd ONC Stock Holding History

Raymond James & Associates’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.2M Sell
14,250
-7,025
-33% -$1.26M ﹤0.01% 1933
2024
Q2 		$3.04M Buy
21,275
+76
+0.4% +$11.7K ﹤0.01% 1914
2024
Q1 		$3.32M Buy
21,199
+8,602
+68% +$1.39M ﹤0.01% 1849
2023
Q4 		$2.27M Sell
12,597
-478
-4% -$86.5K ﹤0.01% 2028
2023
Q3 		$2.35M Sell
13,075
-2,821
-18% -$558K ﹤0.01% 1919
2023
Q2 		$2.83M Sell
15,896
-1,277
-7% -$294K ﹤0.01% 1848
2023
Q1 		$3.7M Buy
17,173
+2,402
+16% +$576K ﹤0.01% 1669
2022
Q4 		$3.25M Buy
14,771
+176
+1% +$32.3K ﹤0.01% 1700
2022
Q3 		$1.97M Sell
14,595
-425
-3% -$73K ﹤0.01% 1964
2022
Q2 		$2.43M Sell
15,020
-253
-2% -$39.5K ﹤0.01% 1873
2022
Q1 		$2.88M Buy
15,273
+3,047
+25% +$648K ﹤0.01% 1880
2021
Q4 		$3.31M Buy
12,226
+304
+3% +$103K ﹤0.01% 1823
2021
Q3 		$4.33M Buy
11,922
+1,259
+12% +$412K ﹤0.01% 1592
2021
Q2 		$3.66M Buy
10,663
+6,046
+131% +$2M ﹤0.01% 1709
2021
Q1 		$1.61M Buy
4,617
+1,067
+30% +$353K ﹤0.01% 2169
2020
Q4 		$917K Sell
3,550
-2,198
-38% -$605K ﹤0.01% 2408
2020
Q3 		$1.65M Buy
5,748
+3,546
+161% +$833K ﹤0.01% 1878
2020
Q2 		$415K Buy
+2,202
New +$358K ﹤0.01% 2720
2020
Q1 		– Sell
-1,692
Closed -$280K – 3754
2019
Q4 		$280K Buy
+1,692
New +$281K ﹤0.01% 3123
2019
Q1 		– Sell
-3,050
Closed -$428K – 3730
2018
Q4 		$428K Buy
3,050
+476
+18% +$63.1K ﹤0.01% 2640
2018
Q3 		$443K Buy
+2,574
New +$433K ﹤0.01% 2793
2018
Q2 		– Sell
-1,529
Closed -$257K – 3684
2018
Q1 		$257K Buy
+1,529
New +$207K ﹤0.01% 2989

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Raymond James & Associates's ONC Position: Q3 2024 in Review

Raymond James & Associates reduced its BeOne Medicines Ltd (ONC) stake by 33% in Q3 2024, selling an estimated $1.26M and leaving 14,250 shares worth $3.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1933.

Raymond James & Associates first reported a position in ONC in Q1 2018 and has held it in 22 quarters since. The position peaked at $4.33M in Q3 2021. 228 funds tracked by Wall St. Rank hold ONC as of Q3 2024.

  • Raymond James & Associates held 14,250 shares of BeOne Medicines Ltd worth $3.2M as of Q3 2024.
  • Raymond James & Associates sold 7,025 BeOne Medicines Ltd shares in Q3 2024, an estimated $1.26M.
  • BeOne Medicines Ltd made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1933 holding.
  • Raymond James & Associates first reported a position in BeOne Medicines Ltd in Q1 2018 and has held it in 22 quarters since.
  • Raymond James & Associates's BeOne Medicines Ltd position peaked at $4.33M in Q3 2021.
  • 228 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.